Milbeguard Duo 4 mg / 10 mg film-coated tablets for small cats and kittens

Riik: Iirimaa

keel: inglise

Allikas: HPRA (Health Products Regulatory Authority)

Toimeaine:

Milbemycin oxime; Praziquantel

Saadav alates:

Ceva Santé Animale

ATC kood:

QP54AB51

INN (Rahvusvaheline Nimetus):

Milbemycin oxime; Praziquantel

Ravimvorm:

Film-coated tablet

Retsepti tüüp:

POM: Prescription Only Medicine as defined in relevant national legislation

Terapeutiline ala:

milbemycin oxime, combinations

Loa andmise kuupäev:

2024-01-19

Toote omadused

1
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Milbeguard Duo 4 mg / 10 mg film-coated tablets for small cats and
kittens
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains:
ACTIVE SUBSTANCES:
Milbemycin oxime
4 mg
Praziquantel
10 mg
EXCIPIENTS:
QUALITATIVE
COMPOSITION OF EXCIPIENTS AND
OTHER CONSTITUENTS
Core:
Povidone
Croscarmellose sodium
Chicken flavour*
Lactose monohydrate
Cellulose microcrystalline
Silica, colloidal anhydrous
Magnesium stearate
Coat:
Polyvinyl alcohol (E1203)
Titanium dioxide (E171)
Macrogol (E1521)
Talc (E553b)
Iron oxide yellow (E172)
_*Artificial origin _
Oblong tablet, beige to yellowish brown, scored on one side. The
tablet can be divided into two equal
parts.
3.
CLINICAL INFORMATION
3.1
TARGET SPECIES
Cats weighing at least 0.5 kg
3.2
INDICATIONS FOR USE FOR EACH TARGET SPECIES
In cats: treatment of mixed infections by immature and adult cestodes
and nematodes of the following
species:
- Cestodes:
_Dipylidium caninum _
_Taenia _
spp
_. _
2
_Echinococcus multilocularis _
- Nematodes:
_Ancylostoma tubaeforme _
_Toxocara cati _
Prevention of heartworm disease (
_Dirofilaria immitis_
) if concomitant treatment against cestodes is
indicated.
3.3
CONTRAINDICATIONS
Do not use in cats of less than 6 weeks of age and/or weighing less
than 0.5 kg.
Do not use in cases of hypersensitivity to the active substances or to
any of the excipients.
3.4
SPECIAL WARNINGS
Unnecessary use of antiparasitics or use deviating from the
instructions given in the SPC may increase
the resistance selection pressure and lead to reduced efficacy. The
decision to use the product should be
based on confirmation of the parasitic species and burden, or of the
risk of infection based on its
epidemiological features, for each individual animal.
It is recommended to treat all the animals living in the same
household concomitantly.
When infection with the cestode
_D. caninum_
has been confirmed, concomitant treatment against
intermediate hosts, such as fleas and lice, should be discussed with a
veterinarian to p